George Maughan, MD
Family Medicine · Richmond, VANPI 1558323824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $653 and has fallen 96.9% since, to $20 in 2025.
Across 156 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$262
- Boehringer Ingelheim$251
- GSK$214
- Novo Nordisk$181
- AbbVie$160
- Johnson & Johnson$139
- plus $1K from 28 others
Across 2 payments — averaging $9397.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$19K
What the payments were for
- Food & beverage$2,55299%
- Entertainment$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $262 |
| Boehringer Ingelheim | 15 | $251 |
| GSK | 15 | $214 |
| Novo Nordisk | 11 | $181 |
| AbbVie(2 entities) | 9 | $160 |
| Johnson & Johnson | 10 | $139 |
| Pfizer | 8 | $131 |
| Amgen | 6 | $129 |
| AstraZeneca | 9 | $120 |
| Bayer | 5 | $93 |
| Novartis | 6 | $85 |
| Astellas Pharma US Inc | 5 | $85 |
| Esperion Therapeutics, Inc. | 5 | $81 |
| Abbott | 5 | $77 |
| Biogen | 3 | $56 |
| Dynavax Technologies Corporation | 2 | $52 |
| Inspire Medical Systems, Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $44 |
| Scilex Pharmaceuticals Inc. | 2 | $40 |
| Mylan Specialty L.p. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Philips North America LLC | 2 | $33 |
| Merck | 2 | $31 |
| Lundbeck LLC | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Optos, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,569 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $21,417 |
| JardianceEmpagliflozin | 14 | $9,509 |
| NorvascAmlodipine Besylate | 15 | $2,694 |
| SynthroidLevothyroxine Sodium | 20 | $1,106 |
| Duloxetine Hcl | 30 | $1,076 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $967 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $810 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $783 |
| Losartan Potassium | 51 | $657 |
| Atorvastatin Calcium | 51 | $565 |
| Metoprolol Succinate | 28 | $541 |
| Levothyroxine Sodium | 42 | $419 |
| Trazodone Hcl | 46 | $386 |
| Allopurinol | 18 | $385 |
| Amlodipine Besylate | 62 | $359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $131 | $21,41722 claims |
| Boehringer IngelheimJardiance | $251 | $9,50914 claims |
| AbbVieSynthroid | $160 | $1,10620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- James FosterRichmond$27K
- Daniel DavidRichmond$16K
- Douglas KlassettRichmond$16K
- James ZelenakRichmond$15K
- David SteinRichmond$15K
- Richard TateRichmond$14K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.